Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Eli Lilly announced Tuesday single-dose vials of weight loss drug Zepbound are now available for patients with a prescription ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving ...

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...